CD274 and chordoma: No differences in chordoma cell PD-L1 positivity, CSC burden, or CSC PD-L1 positivity were identified with clinical correlations of patient age, tumor anatomic site of origin, disease stage, or radiotherapy treatment exposure (Supplementary Figure 2).